SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience’s net profit rises 57% in Q1

10 Aug 2024 Evaluate

Supriya Lifescience has reported results for first quarter ended June 30, 2024 (Q1FY25). 

The company has reported 56.58% rise in its net profit of Rs 44.64 crore for Q1FY25 as compared to Rs 28.51 crore for the same quarter in the previous year. Total income of the company increased by 20.68% at Rs 162.85 crore for Q1FY25 as compared to Rs 134.94 crore for the corresponding quarter previous year.

Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.


Supriya Lifescience Share Price

636.90 -1.05 (-0.16%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×